Hormonal
Once-daily oral semaglutide (3–14 mg) significantly reduces HbA1c (mean -1.16%-points) and body weight (mean -5.84 kg) in adults with type 2 diabetes over 34–44 weeks, with 47.5% achieving HbA1c < 7.0% and 35.5% achieving composite targets (HbA1c reduction ≥ 1.0%-points plus body weight reduction ≥ 5%).
If you have Type 2 Diabetes and are struggling with blood sugar and weight, oral semaglutide is a proven, once-daily option that can significantly lower your HbA1c and help you lose weight. Most people find it easy to take, and while stomach issues can happen, they are usually mild. It is particularly useful if you want to avoid injections.
Significant improvements from BL to EOS were observed for HbA1c and BW (estimated change [95% confidence interval]: − 1.16%-points [− 1.48 to − 0.85]; p < 0.0001, and − 5.84 kg [− 6.88 to − 4.80]; p < 0.0001, respectively)... At EOS, 47.5% of participants had an HbA1c level < 7.0%; 41.8% and 35.5% of participants achieved composite endpoints of HbA1c reduction ≥ 1.0%-points plus BW reduction ≥ 3% or ≥ 5%, respectively.
Why this rating
Phase 4, multicentre, prospective, non-interventional real-world study (N=187) with robust statistical analysis (MMRM), though observational design limits causal inference compared to RCTs.
Source
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study
William van Houtum et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01588-5
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →